
<div id="jpedal" style="overflow: hidden; position: relative; width: 909px; height: 1212px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_1{left:72px;top:98px;letter-spacing:0.6px;word-spacing:17.4px;}
#t2_1{left:72px;top:116px;letter-spacing:0.6px;word-spacing:2.4px;}
#t3_1{left:91px;top:133px;word-spacing:8.1px;}
#t4_1{left:72px;top:151px;word-spacing:0.8px;}
#t5_1{left:72px;top:168px;}
#t6_1{left:72px;top:186px;letter-spacing:-0.3px;word-spacing:11.4px;}
#t7_1{left:148px;top:186px;}
#t8_1{left:159px;top:186px;}
#t9_1{left:172px;top:186px;letter-spacing:-0.2px;word-spacing:10.9px;}
#ta_1{left:72px;top:204px;letter-spacing:-0.3px;word-spacing:9.1px;}
#tb_1{left:372px;top:204px;}
#tc_1{left:382px;top:204px;}
#td_1{left:396px;top:204px;letter-spacing:-0.3px;}
#te_1{left:72px;top:221px;letter-spacing:-0.2px;word-spacing:13.2px;}
#tf_1{left:72px;top:239px;letter-spacing:-0.2px;word-spacing:7px;}
#tg_1{left:72px;top:257px;letter-spacing:-0.2px;word-spacing:18.9px;}
#th_1{left:72px;top:274px;letter-spacing:-0.3px;word-spacing:2.3px;}
#ti_1{left:91px;top:292px;word-spacing:-0.8px;}
#tj_1{left:72px;top:310px;word-spacing:13.1px;}
#tk_1{left:72px;top:327px;word-spacing:2.5px;}
#tl_1{left:72px;top:345px;word-spacing:17.1px;}
#tm_1{left:72px;top:363px;letter-spacing:-0.5px;word-spacing:4.3px;}
#tn_1{left:72px;top:398px;word-spacing:4.3px;}
#to_1{left:72px;top:416px;word-spacing:4.9px;}
#tp_1{left:72px;top:433px;word-spacing:4.1px;}
#tq_1{left:72px;top:451px;word-spacing:-0.1px;}
#tr_1{left:72px;top:469px;word-spacing:8.5px;}
#ts_1{left:72px;top:486px;word-spacing:10.2px;}
#tt_1{left:72px;top:504px;word-spacing:-2.3px;}
#tu_1{left:72px;top:522px;word-spacing:7px;}
#tv_1{left:72px;top:539px;word-spacing:-0.9px;}
#tw_1{left:72px;top:557px;word-spacing:10.3px;}
#tx_1{left:72px;top:575px;word-spacing:9.8px;}
#ty_1{left:72px;top:592px;}
#tz_1{left:142px;top:592px;}
#t10_1{left:159px;top:592px;word-spacing:7.6px;}
#t11_1{left:72px;top:610px;word-spacing:0.7px;}
#t12_1{left:72px;top:627px;word-spacing:-0.5px;}
#t13_1{left:72px;top:645px;word-spacing:4.4px;}
#t14_1{left:91px;top:663px;letter-spacing:0.5px;word-spacing:4.4px;}
#t15_1{left:72px;top:680px;letter-spacing:0.5px;word-spacing:8px;}
#t16_1{left:72px;top:698px;letter-spacing:0.5px;word-spacing:27.1px;}
#t17_1{left:465px;top:98px;letter-spacing:0.5px;word-spacing:23px;}
#t18_1{left:465px;top:116px;letter-spacing:0.5px;word-spacing:6.9px;}
#t19_1{left:465px;top:133px;letter-spacing:0.5px;word-spacing:15.4px;}
#t1a_1{left:465px;top:151px;letter-spacing:0.5px;word-spacing:7.8px;}
#t1b_1{left:465px;top:168px;letter-spacing:0.5px;word-spacing:22.2px;}
#t1c_1{left:465px;top:186px;letter-spacing:0.5px;word-spacing:8.9px;}
#t1d_1{left:465px;top:204px;letter-spacing:0.5px;word-spacing:17.9px;}
#t1e_1{left:568px;top:204px;letter-spacing:0.5px;}
#t1f_1{left:586px;top:204px;letter-spacing:31.3px;}
#t1g_1{left:611px;top:204px;}
#t1h_1{left:615px;top:204px;letter-spacing:10.8px;}
#t1i_1{left:651px;top:204px;letter-spacing:21.1px;}
#t1j_1{left:698px;top:204px;}
#t1k_1{left:702px;top:204px;}
#t1l_1{left:709px;top:204px;letter-spacing:0.6px;}
#t1m_1{left:722px;top:204px;}
#t1n_1{left:730px;top:204px;}
#t1o_1{left:736px;top:204px;letter-spacing:31.4px;}
#t1p_1{left:759px;top:204px;letter-spacing:16px;}
#t1q_1{left:785px;top:204px;}
#t1r_1{left:792px;top:204px;}
#t1s_1{left:798px;top:204px;}
#t1t_1{left:805px;top:204px;}
#t1u_1{left:813px;top:204px;}
#t1v_1{left:817px;top:204px;}
#t1w_1{left:824px;top:204px;}
#t1x_1{left:465px;top:221px;letter-spacing:0.5px;word-spacing:26.1px;}
#t1y_1{left:465px;top:239px;letter-spacing:0.5px;word-spacing:16.8px;}
#t1z_1{left:465px;top:257px;letter-spacing:0.5px;word-spacing:14.1px;}
#t20_1{left:465px;top:274px;letter-spacing:0.5px;word-spacing:4.5px;}
#t21_1{left:465px;top:292px;letter-spacing:0.5px;word-spacing:2.3px;}
#t22_1{left:465px;top:310px;letter-spacing:0.5px;word-spacing:7.2px;}
#t23_1{left:465px;top:341px;word-spacing:3.6px;}
#t24_1{left:573px;top:341px;word-spacing:3.8px;}
#t25_1{left:465px;top:377px;}
#t26_1{left:470px;top:406px;}
#t27_1{left:491px;top:406px;word-spacing:8.8px;}
#t28_1{left:491px;top:422px;word-spacing:11.5px;}
#t29_1{left:491px;top:438px;}
#t2a_1{left:470px;top:454px;}
#t2b_1{left:491px;top:454px;word-spacing:11.1px;}
#t2c_1{left:491px;top:470px;word-spacing:13.1px;}
#t2d_1{left:491px;top:487px;word-spacing:3.8px;}
#t2e_1{left:650px;top:520px;word-spacing:3.9px;}
#t2f_1{left:702px;top:518px;}
#t2g_1{left:707px;top:520px;word-spacing:3.6px;}
#t2h_1{left:807px;top:518px;}
#t2i_1{left:826px;top:519px;}
#t2j_1{left:470px;top:534px;}
#t2k_1{left:474px;top:536px;word-spacing:3.7px;}
#t2l_1{left:531px;top:551px;}
#t2m_1{left:535px;top:552px;word-spacing:3.6px;}
#t2n_1{left:602px;top:568px;word-spacing:3.7px;}
#t2o_1{left:497px;top:583px;}
#t2p_1{left:501px;top:584px;word-spacing:3.8px;}
#t2q_1{left:475px;top:616px;word-spacing:3.7px;}
#t2r_1{left:571px;top:632px;word-spacing:3.7px;}
#t2s_1{left:706px;top:649px;word-spacing:3.9px;}
#t2t_1{left:512px;top:665px;word-spacing:3.9px;}
#t2u_1{left:597px;top:665px;}
#t2v_1{left:753px;top:665px;word-spacing:3.8px;}
#t2w_1{left:465px;top:699px;}
#t2x_1{left:72px;top:756px;word-spacing:-0.1px;}
#t2y_1{left:72px;top:772px;word-spacing:4.3px;}
#t2z_1{left:72px;top:790px;word-spacing:4.3px;}
#t30_1{left:72px;top:816px;word-spacing:4.4px;}
#t31_1{left:72px;top:858px;word-spacing:4.3px;}
#t32_1{left:72px;top:875px;word-spacing:17.9px;}
#t33_1{left:72px;top:893px;word-spacing:9.6px;}
#t34_1{left:72px;top:911px;word-spacing:0.7px;}
#t35_1{left:72px;top:928px;word-spacing:14.7px;}
#t36_1{left:72px;top:946px;word-spacing:7.2px;}
#t37_1{left:72px;top:964px;word-spacing:3.8px;}
#t38_1{left:72px;top:981px;word-spacing:2.9px;}
#t39_1{left:72px;top:999px;word-spacing:14px;}
#t3a_1{left:72px;top:1017px;word-spacing:7.2px;}
#t3b_1{left:72px;top:1034px;word-spacing:1.4px;}
#t3c_1{left:72px;top:1052px;word-spacing:7.5px;}
#t3d_1{left:72px;top:1069px;word-spacing:4.4px;}
#t3e_1{left:72px;top:1087px;word-spacing:2.3px;}
#t3f_1{left:72px;top:1105px;word-spacing:16.8px;}
#t3g_1{left:72px;top:1122px;word-spacing:3.2px;}
#t3h_1{left:465px;top:756px;word-spacing:4.3px;}
#t3i_1{left:465px;top:773px;word-spacing:-0.1px;}
#t3j_1{left:465px;top:791px;word-spacing:10.4px;}
#t3k_1{left:465px;top:809px;word-spacing:7.1px;}
#t3l_1{left:465px;top:826px;word-spacing:1.8px;}
#t3m_1{left:465px;top:844px;word-spacing:1.7px;}
#t3n_1{left:465px;top:862px;word-spacing:4.4px;}
#t3o_1{left:465px;top:893px;word-spacing:4.1px;}
#t3p_1{left:465px;top:911px;word-spacing:5.9px;}
#t3q_1{left:465px;top:928px;word-spacing:15.9px;}
#t3r_1{left:465px;top:946px;word-spacing:-2.7px;}
#t3s_1{left:465px;top:964px;word-spacing:6.8px;}
#t3t_1{left:465px;top:981px;}
#t3u_1{left:531px;top:981px;}
#t3v_1{left:548px;top:981px;word-spacing:4.4px;}
#t3w_1{left:465px;top:999px;word-spacing:14.8px;}
#t3x_1{left:465px;top:1017px;word-spacing:13px;}
#t3y_1{left:465px;top:1034px;word-spacing:11.3px;}
#t3z_1{left:465px;top:1052px;word-spacing:4.8px;}
#t40_1{left:465px;top:1069px;word-spacing:0.2px;}
#t41_1{left:465px;top:1087px;word-spacing:8px;}
#t42_1{left:465px;top:1105px;word-spacing:1px;}
#t43_1{left:780px;top:1105px;}
#t44_1{left:801px;top:1105px;}
#t45_1{left:465px;top:1122px;word-spacing:1.2px;}
#t46_1{left:324px;top:50px;letter-spacing:6.5px;word-spacing:4.5px;}
#t47_1{left:72px;top:47px;}

.s6_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: HCEEKA-AdvP4DF6121;
	color: rgb(0,0,0);
}

.s11_1{
	FONT-SIZE: 28.4px;
	FONT-FAMILY: HCEEJP-AdvP4DF60F1;
	color: rgb(0,0,0);
}

.s14_1{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: HCEEGN-AdvP4DF6141;
	color: rgb(0,0,0);
}

.s5_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,104,156);
}

.s10_1{
	FONT-SIZE: 28.4px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,104,156);
}

.s1_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,0,0);
}

.s2_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: HCEEJP-AdvP4DF60F1;
	color: rgb(0,0,0);
}

.s3_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: HCEEIO-AdvP4C4E511;
	color: rgb(0,0,0);
}

.s4_1{
	FONT-SIZE: 51.8px;
	FONT-FAMILY: HCEEGN-AdvP4DF6141;
	color: rgb(0,0,0);
}

.s8_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(35,31,32);
}

.s12_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: HCEEJP-AdvP4DF60F1;
	color: rgb(0,0,0);
}

.s13_1{
	FONT-SIZE: 39px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,0,0);
}

.s7_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,0,0);
}

.s9_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: HCEEHN-AdvP4DF60E1;
	color: rgb(0,104,156);
}

.v1_1{
	-webkit-transform: scale(0.259, 0.25);
	-ms-transform: scale(0.259, 0.25);
	-moz-transform: scale(0.259, 0.25);
	-o-transform: scale(0.259, 0.25);
}

.v2_1{
	-webkit-transform: scale(0.292, 0.25);
	-ms-transform: scale(0.292, 0.25);
	-moz-transform: scale(0.292, 0.25);
	-o-transform: scale(0.292, 0.25);
}

#form1_1{	border-style:none;	z-index:2;	position: absolute;	left:142px;	top:594px;	width:19px;	height:14px;	text-align:left;	background: transparent;	font:normal 10px Arial, Helvetica, sans-serif;}
#form1_2{	border-style:none;	z-index:2;	position: absolute;	left:779px;	top:1106px;	width:19px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_3{	border-style:none;	z-index:2;	position: absolute;	left:530px;	top:983px;	width:19px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_4{	border-style:none;	z-index:2;	position: absolute;	left:567px;	top:205px;	width:20px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_5{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:439px;	width:93px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_6{	border-style:none;	z-index:2;	position: absolute;	left:596px;	top:666px;	width:154px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_7{	border-style:none;	z-index:2;	position: absolute;	left:465px;	top:700px;	width:242px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_8{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:472px;	width:341px;	height:11px;	text-align:left;	background: transparent;	font:normal 7px Arial, Helvetica, sans-serif;}
#form1_9{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:488px;	width:323px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_10{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:455px;	width:341px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_11{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:407px;	width:341px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_12{	border-style:none;	z-index:2;	position: absolute;	left:491px;	top:423px;	width:341px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts1" type="text/css" >

@font-face {
	font-family: HCEEJP-AdvP4DF60F1;
	src: url("1/fonts/HCEEJP-AdvP4DF60F.woff") format("woff");
}

@font-face {
	font-family: HCEEKA-AdvP4DF6121;
	src: url("1/fonts/HCEEKA-AdvP4DF612.woff") format("woff");
}

@font-face {
	font-family: HCEEIO-AdvP4C4E511;
	src: url("1/fonts/HCEEIO-AdvP4C4E51.woff") format("woff");
}

@font-face {
	font-family: HCEEGN-AdvP4DF6141;
	src: url("1/fonts/HCEEGN-AdvP4DF614.woff") format("woff");
}

@font-face {
	font-family: HCEEHN-AdvP4DF60E1;
	src: url("1/fonts/HCEEHN-AdvP4DF60E.woff") format("woff");
}

</style>
<div id="t1_1" class="t s1_1">radiographic progression-free survival (rPFS) and overall</div>
<div id="t2_1" class="t s1_1">survival (OS).</div>
<div id="t3_1" class="t v1_1 s1_1">A total of 1717 patients were recruited. The enzaluta-</div>
<div id="t4_1" class="t v1_1 s1_1">mide group had a significantly better rate of rPFS at 12 mo,</div>
<div id="t5_1" class="t v1_1 s1_1">65%, compared with 14% in the placebo group (hazard ratio</div>
<div id="t6_1" class="t v1_1 s1_1">[HR]: 0.19;</div>
<div id="t7_1" class="t v1_1 s2_1">p</div>
<div id="t8_1" class="t v1_1 s3_1">&lt;</div>
<div id="t9_1" class="t v1_1 s1_1">0.001). In addition, the risk of death was</div>
<div id="ta_1" class="t v1_1 s1_1">reduced by 29% with enzalutamide (HR: 0.71;</div>
<div id="tb_1" class="t v1_1 s2_1">p</div>
<div id="tc_1" class="t v1_1 s3_1">&lt;</div>
<div id="td_1" class="t v1_1 s1_1">0.001).</div>
<div id="te_1" class="t v1_1 s1_1">Enzalutamide was also superior in times to initiation of</div>
<div id="tf_1" class="t v1_1 s1_1">chemotherapy, to first skeletal-related event, and to pros-</div>
<div id="tg_1" class="t v1_1 s1_1">tate-specific antigen progression as well as in rates of</div>
<div id="th_1" class="t v1_1 s1_1">complete and partial soft tissue disease response.</div>
<div id="ti_1" class="t v1_1 s1_1">After reviewing interim results, the trial was premature-</div>
<div id="tj_1" class="t v1_1 s1_1">ly terminated, and enzalutamide was offered to eligible</div>
<div id="tk_1" class="t v1_1 s1_1">patients receiving the placebo. The authors concluded that</div>
<div id="tl_1" class="t v1_1 s1_1">enzalutamide had significant benefits for patients with</div>
<div id="tm_1" class="t v1_1 s1_1">mCRPC who are chemotherapy naı¨ve.</div>
<div id="tn_1" class="t s4_1">Experts’ comments:</div>
<div id="to_1" class="t s1_1">This important randomised controlled trial has been eagerly</div>
<div id="tp_1" class="t s1_1">awaited and does not disappoint. It demonstrates that enza-</div>
<div id="tq_1" class="t s1_1">lutamide, a well-tolerated and easily administered oral agent,</div>
<div id="tr_1" class="t s1_1">provides very significant reductions in rPFS and OS in men</div>
<div id="ts_1" class="t s1_1">with mCRPC prior to chemotherapy. The respective HRs of</div>
<div id="tt_1" class="t s1_1">0.19 and 0.71 are most impressive. The other interesting agent</div>
<div id="tu_1" class="t s1_1">in this disease space, abiraterone, is also well tolerated and</div>
<div id="tv_1" class="t s1_1">easily administered (but requires concomitant use of prednis-</div>
<div id="tw_1" class="t s1_1">olone); however, it failed to demonstrate an OS advantage</div>
<div id="tx_1" class="t s1_1">when its phase 3 study was published in a similar patient</div>
<div id="ty_1" class="t s1_1">population</div>
<div id="tz_1" class="t s5_1">[1]</div>
<div id="t10_1" class="t s1_1">. This may be explained by the trial stopping</div>
<div id="t11_1" class="t s1_1">early due to the very impressive reductions in rPFS at interim</div>
<div id="t12_1" class="t s1_1">analysis; however, it is noted that the PREVAIL study was also</div>
<div id="t13_1" class="t s1_1">stopped early for similar reasons.</div>
<div id="t14_1" class="t v1_1 s1_1">One might expect that in the increasingly competitive</div>
<div id="t15_1" class="t v1_1 s1_1">mCRPC market, the data from the PREVAIL study would</div>
<div id="t16_1" class="t v1_1 s1_1">lead to enzalutamide becoming the first choice for</div>
<div id="t17_1" class="t v1_1 s1_1">therapy in this patient population. This may be so;</div>
<div id="t18_1" class="t v1_1 s1_1">however, CRPC is still progressive in many patients, and</div>
<div id="t19_1" class="t v1_1 s1_1">multiple agents may be required to offer a maximum</div>
<div id="t1a_1" class="t v1_1 s1_1">survival benefit. The optimal sequence and combination</div>
<div id="t1b_1" class="t v1_1 s1_1">of therapies to ensure maximum survival, maximum</div>
<div id="t1c_1" class="t v1_1 s1_1">quality of life, and maximum cost effectiveness are still</div>
<div id="t1d_1" class="t v1_1 s1_1">far from clear</div>
<div id="t1e_1" class="t v1_1 s5_1">[2]</div>
<div id="t1f_1" class="t v1_1 s1_1">.W</div>
<div id="t1g_1" class="t v1_1 s1_1">i</div>
<div id="t1h_1" class="t v1_1 s1_1">thsu</div>
<div id="t1i_1" class="t v1_1 s1_1">chap</div>
<div id="t1j_1" class="t v1_1 s1_1">l</div>
<div id="t1k_1" class="t v1_1 s1_1">e</div>
<div id="t1l_1" class="t v1_1 s1_1">th</div>
<div id="t1m_1" class="t v1_1 s1_1">o</div>
<div id="t1n_1" class="t v1_1 s1_1">r</div>
<div id="t1o_1" class="t v1_1 s1_1">ao</div>
<div id="t1p_1" class="t v1_1 s1_1">fth</div>
<div id="t1q_1" class="t v1_1 s1_1">e</div>
<div id="t1r_1" class="t v1_1 s1_1">r</div>
<div id="t1s_1" class="t v1_1 s1_1">a</div>
<div id="t1t_1" class="t v1_1 s1_1">p</div>
<div id="t1u_1" class="t v1_1 s1_1">i</div>
<div id="t1v_1" class="t v1_1 s1_1">e</div>
<div id="t1w_1" class="t v1_1 s1_1">s</div>
<div id="t1x_1" class="t v1_1 s1_1">available, it may be some time before the optimal</div>
<div id="t1y_1" class="t v1_1 s1_1">sequence and combination of therapies is established.</div>
<div id="t1z_1" class="t v1_1 s1_1">In the meantime, this excellent study gives us further</div>
<div id="t20_1" class="t v1_1 s1_1">hope that a well-tolerated and easily administered agent</div>
<div id="t21_1" class="t v1_1 s1_1">can offer a very significant survival benefit for patients in</div>
<div id="t22_1" class="t v1_1 s1_1">this otherwise perilous situation.</div>
<div id="t23_1" class="t s6_1">Conﬂicts of interest:</div>
<div id="t24_1" class="t s7_1">The authors have nothing to disclose.</div>
<div id="t25_1" class="t v1_1 s4_1">References</div>
<div id="t26_1" class="t s8_1">[1]</div>
<div id="t27_1" class="t s9_1">Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic</div>
<div id="t28_1" class="t s9_1">prostate cancer without previous chemotherapy. N Engl J Med</div>
<div id="t29_1" class="t s9_1">2013;368:138–48.</div>
<div id="t2a_1" class="t s8_1">[2]</div>
<div id="t2b_1" class="t s9_1">Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on</div>
<div id="t2c_1" class="t s9_1">prostate cancer. Part II: treatment of advanced, relapsing, and</div>
<div id="t2d_1" class="t s9_1">castration-resistant prostate cancer. Eur Urol 2014;65:467–79.</div>
<div id="t2e_1" class="t s7_1">Ken Chow</div>
<div id="t2f_1" class="t v2_1 s10_1">a</div>
<div id="t2g_1" class="t s7_1">, Declan G. Murphy</div>
<div id="t2h_1" class="t v2_1 s10_1">a,b,c,</div>
<div id="t2i_1" class="t s9_1">*</div>
<div id="t2j_1" class="t v2_1 s11_1">a</div>
<div id="t2k_1" class="t s12_1">Department of Urology, Royal Melbourne Hospital, Melbourne, Australia</div>
<div id="t2l_1" class="t v2_1 s11_1">b</div>
<div id="t2m_1" class="t s12_1">Division of Cancer Surgery, Peter MacCallum Cancer Centre,</div>
<div id="t2n_1" class="t s12_1">University of Melbourne, Melbourne, Australia</div>
<div id="t2o_1" class="t v2_1 s11_1">c</div>
<div id="t2p_1" class="t s12_1">Epworth Prostate Centre, Epworth Healthcare, Richmond, Australia</div>
<div id="t2q_1" class="t s7_1">*Corresponding author. Division of Cancer Surgery, Peter MacCallum</div>
<div id="t2r_1" class="t s7_1">Cancer Centre, St. Andrews Place, East Melbourne,</div>
<div id="t2s_1" class="t s7_1">Victoria 3002, Australia.</div>
<div id="t2t_1" class="t s7_1">E-mail address:</div>
<div id="t2u_1" class="t s9_1">declan.murphy@petermac.org</div>
<div id="t2v_1" class="t s7_1">(D.G. Murphy).</div>
<div id="t2w_1" class="t s9_1"><a href="http://dx.doi.org/10.1016/j.eururo.2014.07.049" target="_blank">http://dx.doi.org/10.1016/j.eururo.2014.07.049</a></div>
<div id="t2x_1" class="t v1_1 s4_1">Re: Testosterone Lab Testing and Initiation in the United</div>
<div id="t2y_1" class="t v1_1 s4_1">Kingdom and the United States, 2000 to 2011</div>
<div id="t2z_1" class="t v1_1 s1_1">Layton JB, Li D, Meier CR, et al.</div>
<div id="t30_1" class="t s1_1">J Clin Endocrinol Metab 2014;99:835–42</div>
<div id="t31_1" class="t s4_1">Experts’ summary:</div>
<div id="t32_1" class="t s1_1">The retrospective cohort study by Layton and colleagues</div>
<div id="t33_1" class="t s1_1">sought to describe the patterns of testosterone testing and</div>
<div id="t34_1" class="t s1_1">testosterone prescriptions in men in the United Kingdom and</div>
<div id="t35_1" class="t s1_1">the United States. The authors utilized data from general</div>
<div id="t36_1" class="t s1_1">practitioner health care records in the United Kingdom and</div>
<div id="t37_1" class="t s1_1">from both commercial and Medicare insurance claims in the</div>
<div id="t38_1" class="t s1_1">United States between 2000 and 2011. This study found that</div>
<div id="t39_1" class="t s1_1">testosterone testing rates increased in both countries and</div>
<div id="t3a_1" class="t s1_1">that new testing in untreated patients rose threefold in the</div>
<div id="t3b_1" class="t s1_1">United Kingdom and more than fourfold in the United States.</div>
<div id="t3c_1" class="t s1_1">This study observed that a significant proportion of men in</div>
<div id="t3d_1" class="t s1_1">their reproductive years received testosterone supplementa-</div>
<div id="t3e_1" class="t s1_1">tion. Men aged 18–39 yr accounted for a significant minority</div>
<div id="t3f_1" class="t s1_1">of new testosterone prescriptions (United Kingdom: 16%;</div>
<div id="t3g_1" class="t s1_1">United States: 12%), and a higher proportion of US men with</div>
<div id="t3h_1" class="t s1_1">normal or high serum testosterone levels received testoster-</div>
<div id="t3i_1" class="t s1_1">one prescriptions (United Kingdom: 1%; United States: 4–9%).</div>
<div id="t3j_1" class="t s1_1">This discrepancy in testing and diagnosis was also evident</div>
<div id="t3k_1" class="t s1_1">from the fact that in the United Kingdom, 88% of men who</div>
<div id="t3l_1" class="t s1_1">were prescribed testosterone were diagnosed with clinical or</div>
<div id="t3m_1" class="t s1_1">laboratory hypogonadism compared with only 60% of men in</div>
<div id="t3n_1" class="t s1_1">the United States.</div>
<div id="t3o_1" class="t s4_1">Experts’ comments:</div>
<div id="t3p_1" class="t s1_1">The study by Layton et al., using data from both UK and US</div>
<div id="t3q_1" class="t s1_1">cohorts, highlights the discrepancies between a definitive</div>
<div id="t3r_1" class="t s1_1">diagnosis of hypogonadism and interventional treatment. This</div>
<div id="t3s_1" class="t s1_1">study, along with an analysis performed by Baillargeon and</div>
<div id="t3t_1" class="t s1_1">colleagues</div>
<div id="t3u_1" class="t s5_1">[1]</div>
<div id="t3v_1" class="t s1_1">, provides evidence for what we already see in</div>
<div id="t3w_1" class="t s1_1">clinical practice, namely, that the number of testosterone</div>
<div id="t3x_1" class="t s1_1">therapy prescriptions has risen dramatically over the past</div>
<div id="t3y_1" class="t s1_1">decade. Because practitioners have become more aware of</div>
<div id="t3z_1" class="t s1_1">hypogonadism, we would hope to see an increase in labora-</div>
<div id="t40_1" class="t s1_1">tory testing but with a smaller increase in testosterone thera-</div>
<div id="t41_1" class="t s1_1">py. These data, however, demonstrate an alarming trend. A</div>
<div id="t42_1" class="t s1_1">subset of patients are not receiving adequate testing</div>
<div id="t43_1" class="t s5_1">[2]</div>
<div id="t44_1" class="t s1_1">prior</div>
<div id="t45_1" class="t s1_1">to initiation of testosterone therapy, and more men are being</div>
<div id="t46_1" class="t s13_1">EUROPEAN UROLOGY 66 (2014) 784–789</div>
<div id="t47_1" class="t s14_1">786</div>

<form>
<input type="button"  tabindex="1"  id="form1_1" name="43 0 R"  pdfFieldName="43 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="12"  id="form1_2" name="54 0 R"  pdfFieldName="54 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="11"  id="form1_3" name="53 0 R"  pdfFieldName="53 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="2"  id="form1_4" name="44 0 R"  pdfFieldName="44 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />
<input type="button"  tabindex="5"  id="form1_5" name="47 0 R"  pdfFieldName="47 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005" />
<input type="button"  tabindex="9"  id="form1_6" name="51 0 R"  pdfFieldName="51 0 R" onclick="window.location.href='mailto:declan.murphy@petermac.org';" style="cursor:pointer;" title="mailto:declan.murphy@petermac.org" />
<input type="button"  tabindex="10"  id="form1_7" name="52 0 R"  pdfFieldName="52 0 R" onclick="window.open('http://dx.doi.org/10.1016/j.eururo.2014.07.049','_blank');" style="cursor:pointer;" title="http://dx.doi.org/10.1016/j.eururo.2014.07.049" />
<input type="button"  tabindex="7"  id="form1_8" name="49 0 R"  pdfFieldName="49 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010" />
<input type="button"  tabindex="8"  id="form1_9" name="50 0 R"  pdfFieldName="50 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010" />
<input type="button"  tabindex="6"  id="form1_10" name="48 0 R"  pdfFieldName="48 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0010" />
<input type="button"  tabindex="3"  id="form1_11" name="45 0 R"  pdfFieldName="45 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005" />
<input type="button"  tabindex="4"  id="form1_12" name="46 0 R"  pdfFieldName="46 0 R" onclick="window.open('http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005','_blank');" style="cursor:pointer;" title="http://refhub.elsevier.com/S0302-2838(14)00739-8/sbref0005" />

</form>
<div id="pg1Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg1"><object width="909" height="1212" data="1/1.svg" type="image/svg+xml" id="pdf1" style="width:909px; height:1212px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 152;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_1");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
